Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Koller

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
New Biotechnology|March 22, 2023
Environmental evaluation of polyhydroxyalkanoates from animal slaughtering waste using Material Input Per Service UnitNadeem Ali, Muhammad Imtiaz Rashid, Mohammad Rehan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A Gertz, Heather Landau, Raymond L Comenzo, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
JAMA Neurology|June 19, 2018
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical TrialJoseph Jankovic, Ira Goodman, Beth Safirstein, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 28, 2018
Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trialFlorian Lipsmeier, Kirsten I Taylor, Timothy Kilchenmann, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
New Biotechnology|March 22, 2023
Environmental evaluation of polyhydroxyalkanoates from animal slaughtering waste using Material Input Per Service UnitNadeem Ali, Muhammad Imtiaz Rashid, Mohammad Rehan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A Gertz, Heather Landau, Raymond L Comenzo, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
JAMA Neurology|June 19, 2018
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical TrialJoseph Jankovic, Ira Goodman, Beth Safirstein, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 28, 2018
Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trialFlorian Lipsmeier, Kirsten I Taylor, Timothy Kilchenmann, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Pageof 8